AttendMe Owl Logo
AttendMe
Evidence Evolution
Internal MedicineInternal Medicine

How This Evidence Evolved

IV Fluid Selection

Normal Saline vs Balanced Crystalloids

12.1

Timeline

Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

The Surviving Sepsis Campaign describes potential saline-related adverse effects including hyperchloremic metabolic acidosis, renal vasoconstriction and concern about acute kidney injury. These concerns motivated interest in balanced or buffered solutions; they do not establish clinical superiority by themselves. A 2012 sequential-period ICU study compared chloride-liberal and chloride-restrictive strategies. Injury or failure-class acute kidney injury occurred in 14% versus 8.4%, and renal replacement therapy in 10% versus 6.3%. The study found associations rather than a randomized causal effect, and no hospital-mortality difference.
Proof

Landmark RCTs and pivotal trials that established the evidence base

SMART assigned 15,802 critically ill adults to balanced crystalloids or saline in a cluster-randomized, multiple-crossover trial. Major adverse kidney events within 30 days occurred in 14.3% versus 15.4% (P=0.04). The composite included death, new renal replacement therapy or persistent renal dysfunction; individual components did not differ significantly. SALT-ED enrolled 13,347 noncritically ill patients treated in the emergency department. Hospital-free days, its primary outcome, were identical at a median of 25 days. The secondary kidney-event composite occurred in 4.7% with balanced crystalloids versus 5.6% with saline.
Extension

Follow-up studies, subgroup analyses, and real-world validation

BaSICS randomized 11,052 patients at 75 Brazilian ICUs; 10,520 were available for analysis. Mortality by day 90 was 26.4% with balanced solution versus 27.2% with saline (adjusted HR 0.97, 95% CI 0.90–1.05; P=0.47). PLUS recruited 5,037 patients across 53 ICUs in Australia and New Zealand. Mortality within 90 days was 21.8% with Plasma-Lyte 148 versus 22.0% with saline (P=0.90). PLUS also found no evidence of lower acute kidney injury risk with balanced solution. These trials did not show a mortality advantage, while SMART had found a difference in a composite kidney outcome.
Guidelines

Integration into clinical practice guidelines and recommendations

The Surviving Sepsis Campaign 2021 suggests balanced crystalloids instead of normal saline for resuscitation in adults with sepsis or septic shock: a weak recommendation with low-quality evidence. This recommendation has a defined population and evidence grade.
Surviving Sepsis Campaign Guidelines

Suggest balanced crystalloids instead of normal saline for resuscitation in adults with sepsis or septic shock (weak; low-quality evidence).

Now

Current standard of care and ongoing research directions

Fluid trials have measured different outcomes in different settings. SMART found fewer major adverse kidney events with balanced crystalloids, while SALT-ED found no difference in its primary outcome of hospital-free days. BaSICS and PLUS did not find significantly lower mortality with balanced solutions. These results support careful interpretation of the population and endpoint when comparing fluid strategies; they do not establish a universal advantage across all clinical situations.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

Should hospitals switch from normal saline to balanced crystalloids?+
SMART found major adverse kidney events in 14.3% with balanced crystalloids versus 15.4% with saline. BaSICS and PLUS did not find significantly lower mortality with balanced solutions. Their populations and primary endpoints differed. These trials do not establish that either strategy is superior in every clinical context.
Why did SMART and BaSICS/PLUS reach different conclusions?+
SMART enrolled 15,802 adults at one academic center using a pragmatic cluster-randomized, multiple-crossover design. BaSICS analyzed 10,520 patients at 75 Brazilian ICUs and PLUS recruited 5,037 at 53 Australian and New Zealand ICUs; both were double-blind. SMART primarily measured major adverse kidney events within 30 days; BaSICS and PLUS primarily evaluated 90-day survival or mortality. Differences in setting, design and endpoints limit direct comparisons.
When should normal saline specifically be used?+
In adult critical-care patients with traumatic brain injury, a meta-analysis associated balanced crystalloids with higher 90-day mortality than saline.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026